Introduction to Prostate Cancer

1%) had prostate cancer; there was a median of 3 metastases treated per patient.

Over 97 significantly mutated genes that have been identified in prostate cancer; however, a lack of genomic prostate cancer studies focusing on different racial and ethnic groups and racial mixing pose a serious challenge to universalize these findings.

Into this group of patients, 54% had a family history positive for neoplasia and 23% consisted of either a pancreatic neoplasm, or breast tumor or prostate cancer; 71% was a FDR.

4% with prostate cancer; 51.

MicroRNA (miR)-217 and sirtuin 1 (SIRT1) have been reported to play significant roles in different types of cancer, such as osteosarcoma and prostate cancer; however, the association between miR-217 and SIRT1 in the cell proliferation, apoptosis and invasion of NSCLC remain unknown.

89% had a primary oncological diagnosis of breast or prostate cancer; the average duration of bisphosphonate therapy up to the time of the study is 4.

BACKGROUND Radiotherapy is a commonly used treatment for prostate cancer; however, the side effects may negatively impact on quality of life and cause patients to be less physically active.

TAGLN is usually downregulated in prostate cancer; however, the detailed functions of TAGLN in prostate cancer and how TAGLN is regulated remains unclear.

In this study, we revealed that circNFIA was upregulated in prostate cancer tissues and plasma samples from patients with prostate cancer; circNFIA may play an oncogenic role in prostate cancer.

MATERIAL A prospective study which included 31 patients diagnosed with prostate cancer; Gleason > 7; mean PSA 13.

Specific inclusion criteria for this review were: 1) a publication date between 2013 and the current year; 2) a focus on African American men diagnosed with prostate cancer; 3), randomized or quasi-randomized controlled trials (RCTs), and; 4) evidence-based interventions used by oncologists.

ABSTRACT 68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a well-established imaging modality in patients with prostate cancer; however, PSMA expression is also reported in the tumor-associated neovasculature, including but not limited to hepatocellular carcinoma, breast cancer, and renal cell carcinoma.

We found human PUM1 is highly expressed in a diverse group of cancer, including prostate cancer; enhanced PUM1 expression is also correlated with reduced survival among prostate cancer patients.

Radiotherapy is one of the curative mainstays of prostate cancer; however, its efficacy is often diminished by tumor radioresistance.

Medical androgen deprivation therapy is currently a cornerstone of therapy for prostate cancer; however molecular mechanisms of resistance have emerged leading to castration-resistant prostate cancer that is proliferation of prostate cancer in the setting of low testosterone (< 50 ng/dl).

We report on 3 calculator models: Model 1 included age, race, PSA, prior biopsy status, body mass index, and family history of prostate cancer; Model 2 added digital rectal exam to Model 1 variables; Model 3 added prostate volume to Model 2 variables.

Psma is one of the molecular markers of prostate cancer; a number of studies have demonstrated a direct correlation between the level of psma expression and the tumor grade, stage and aggressiveness.

Keywords: prostate cancer; biopsy; MRI; fusion.

BACKGROUND Prostate-specific antigen (PSA) is a valuable prognostic and predictive biomarker in prostate cancer; however, the significance of PSA at or near the time of death is not well understood.

Clinicians and researchers are looking for potent treatments for the resistant forms of prostate cancer; however, a handful of small molecules used in the treatment of castration-resistant prostate cancer have not shown potent effects owing to the mutations in the AR (Androgen Receptor).

Keywords: prostate cancer; gleason score; extraprostatic extension.

Among these, the developing nanotechnology has introduced several innovative testing technologies and medications for the treatment of prostate cancer; nanotechnology can significantly increase the management operation of prostate cancer by using specific physical and chemical properties, targeting techniques, or anchoring with imaging/pharmacological substances to provide innovative theranostics devices.

Secondary objectives were to examine whether African American men have been screened for prostate cancer; their confidence in making an informed choice about whether PSA testing is right for them; and whether they have talked with their provider about PSA testing and engaged in an informed decision-making process around prostate cancer screening.

Keywords: Prostate cancer; awareness; knowledge; male teachers; Ghana.

7%, 51/55) patients were positive for prostate cancer; 47 (85.

Objectives: 1) to find out the distribution of prostate cancer by risk of progression; 2) to determine the cause-specific survival by risk of progression in prostate cancer; 3) to identify the factors associated with the risk of dying from this cancer.

AR splice variant-7 (AR-V7) is a truncated variant of AR that leads to AR inhibitor therapy resistance in prostate cancer; recent studies have identified AR-V7 in BC and theorized that AR-V7 can have a similar impact.

PBX3 is involved in the progression of gastric cancer, colorectal cancer, and prostate cancer; however, the detailed mechanism by which it promotes tumor growth remains to be elucidated.

0µg) were submitted to a biopsy through the Fast Track; 150 were positive (54,2%) for prostate cancer; and 72% with Gleason score 7 or higher.

Pomegranate also exhibits significant anti-oxidative, anti-hypertensive, cardioprotective and anti-diabetic properties and anti-carcinogenic possessions including prevention of prostate cancer; reduction in colon inflammation, prevention of skin tumorigenesis, improvement in renal function and reduction in metastatic melanoma growth.

Different myosins play either oncogenic or tumor suppressor roles in breast, lung and prostate cancer; however, little is known about their functions in CRC.

Material A prospective study which included 31 patients diagnosed with prostate cancer; Gleason >7; mean PSA 13.

Keywords: Biochemical recurrence; hybrid imaging; positron emission tomography; prostate cancer; prostate-specific membrane antigen.

Prostate-Specific Antigen (PSA), which has high organ specificity and poor cancer specificity, has been widely utilized for the diagnosis and treatment of prostate cancer; though it is not an ideal tumor marker.

Epigenetics play an important role in the pathogenesis of prostate cancer; it is urgent to investigate vital transcription factors in methylation regulation with the aim to develop novel treatment strategies targeting prostate cancer.

1% for prostate cancer; and 23.

To compare urinary complications of robot-assisted radical prostatectomy(RARP) and laparoscopic radical prostatectomy(LRP) in patients with prostate cancer; 2.

9% the sample, the etiology was neoplastic, most commonly multiple myeloma and metastatic disease due to prostate cancer; 21.

Five hotspots have been confirmed: (a) male infertility associated with prostatitis and the molecular mechanisms; (b) diagnosis and treatment of prostatitis; (c) inflammation, pain and bladder irritation symptoms; (d) relationship between chronic prostatitis/chronic pelvic pain syndrome, benign prostatic hyperplasia and prostate cancer; (e) epidemiology, complications of prostatitis and improvement of acupuncture.

Abbreviations: CMA: chaperone-mediated autophagy; HDAC2: histone deacetylase 2; HSPA8/HSC70: heat shock protein family A (Hsp70) member 8; KAT2B: lysine acetyltransferase 2B; LAMP2A: lysosomal associated membrane protein 2A; PCa: prostate cancer; TPD52: tumor protein D52.

We found human PUM1 is highly expressed in a diverse group of cancer, including prostate cancer; enhanced PUM1 expression is also correlated with reduced survival among prostate cancer patients.

Results A total of 32 172 men initiated degarelix or leuprolide for prostate cancer; of them, 9490 (29.

PSMA detected PSL in 12 with prostate cancer; FDG identified PSL in 4 with lymphoma, 3 with colorectal cancer, 2 with lung cancer, and one each with bladder cancer, pelvic sarcoma, and leukemia.

Prostate cancer is the most common cancer among men in the USA.

Methods A retrospective analysis of 102 cases of cervical cancer, 53 cases of rectal cancer and 34 cases of prostate cancer in People′s Hospital of Xinjiang Uygur Autonomous Region from January 2013 to April 2016 was performed.

Psychological distress is prevalent among men with prostate cancer (PCa).

INTRODUCTION AND OBJECTIVES: Lymph node dissection (LND) during radical prostatectomy (RP) for prostate cancer (PCa) aims to provide information for staging and prognosis, while oncological and survival benefits are debatable.

In the experimental study, we apply our approach on SEER-Medicare data related to prostate cancer among African–Americans and white patients.

Prostate cancer is one of the most common cancers in the United States, with an estimated incidence of 164,690 cases, accounting for 9.

The European randomised study of screening for prostate cancer trial (ERSPC) and Prostate cancer intervention versus observation trial (PIVOT) indicate that overtreatment of the low risk prostate cancer is quite common.

Thus in this study, we characterize a novel therapeutic approach that combines USMB with HT to enhance treatment responses in a prostate cancer xenograft model in vivo.

Prostate cancer may be an exception with the modest activity of Sipuleucel T.

Loss of Vaccinia‐H1 related phosphatase (VHR) has been shown to arrest at the G1‐S and G2‐M transitions of the cell cycle, and to increases cell death of prostate cancer cells through JNK activation, suggesting that VHR can be considered as an anticancer target.

Prostate cancer (PCa) is a destructive malignancy with a bad prognosis.

Risk calculators (RCs) such as the European Randomized Study of Screening for Prostate Cancer (ERSPC) RCs have been developed to predict the outcome of prostate biopsies and have been shown to improve diagnostic accuracy compared to PSA alone.

PurposeAlthough prediction tools for prostate cancer (PCa) are essential for high-quality treatment decision-making, little is known about the degree of confidence in existing tools and whether they are used in clinical practice from radiation oncologists (RO) and urologists (URO).

In men, prostate cancer was the most common cancer (4.

INTRODUCTION Human exposure to persistent organic pollutants (POPs) has been linked to genitourinary health-related conditions such as decreased sperm quality, hypospadias, and prostate cancer (PCa).

Prostate cancer (PCa) is a world-wide issue, with rapid increase in its occurrence and mortality.

406 patients treated with VMAT for prostate cancer were analyzed retrospectively.

Interestingly, a mutually exclusive relationship exists between genomic alterations in PTEN and mutations in SPOP in prostate cancer patients, suggesting that altered functions of these two tumor suppressors might share similar or at least partially overlapping mechanisms in tumorigenesis.

Predictive parameters for detection of prostate cancer in gray-zone patients were also investigated.

Despite the lack of a complete understanding of the disparities involved, prostate cancer (PCa) has both higher incidence and death rates in African American Men (AAM) relative to those of Caucasian American Men (CAM).

Material and Methods: Expression level of Wee1 in cervical cancer was evaluated using Oncomine Cervical cancer cell lines, Caski (HPV16+), SiHa (HPV16+) and C33A (HPV-, P53 mut) and LNCap (HPV-, P53 wt, prostate cancer) were used.

Prostate cancer (PCa) is a health issue, but also a great scientific challenge.

Patients are full members of the guideline development groups; however, the question remains how do we truly capture patient values? By inviting a philosopher/medical ethicist to be a member of the GDG, integrating patient values has been explored in our update of the national clinical guideline diagnosis staging and treatment of patients with prostate cancer.

Prostate cancer (PCa) is the second most common malignancy and the sixth leading cause of cancer‐related death among men worldwide.

Intratumoural heterogeneity contributes to local tumour recurrence and variable responses to radiotherapy in prostate cancer.

BackgroundThere is an urgent need for targeted biological therapies for prostate cancer with greater efficacy and less toxicity, particularly for metastatic disease, where current therapies are not curative.